STRATEGIC DIVESTITURES

Jon Eisenberg assisted a Fortune 500 medical technology company in the divestiture of several non-strategic product lines. The project included managing the withdrawal of important products from a worldwide distributor network. The project was completed without incurring distributor litigation or the associated expenses in any country. Additional efforts involved the preservation of intellectual property needed in the future and the out-licensing of IP rights needed by purchasers.